Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.60 |
| ▸ | MSTN | O14793 | 1/20 | 0.59 |
| ▸ | GLP1R | P43220 | 4/20 | 0.59 |
| ▸ | PRLHR | P49683 | 2/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 2/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.55 |
| ▸ | BECN1 | Q14457 | 2/20 | 0.54 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358496 | 0.86 | GLP1R (0.68) | GLP1RNR3C1NPY2RIL23RKEAP1 | |
| SCHEMBL29754464 | 0.81 | IL23R (0.64) | GLP1RIL23R | |
| SCHEMBL29383537 | 0.80 | GLP1R (0.74) | GLP1RNR3C1NPY2RPTH1RCCKBR | |
| SCHEMBL29913332 | 0.79 | GLP1R (0.74) | GLP1RIL23RPTH1RCCKBR | |
| SCHEMBL29358595 | 0.79 | GLP1R (0.68) | GLP1RIL23RPTH1RCCKBR | |
| SCHEMBL29694497 | 0.79 | GLP1R (0.65) | GLP1RCCKBR | |
| SCHEMBL31092855 | 0.79 | IL23R (0.67) | GLP1RNR3C1NPY2RIL23R | |
| SCHEMBL7358806 | 0.79 | IL23R (0.61) | GLP1RIL23RPTH1RCCKBR | |
| SCHEMBL31135025 | 0.79 | PTH1R (0.68) | GLP1RPTH1R | |
| SCHEMBL30506350 | 0.79 | GLP1R (0.68) | GLP1RNPY2RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473522-B2 | Methods and systems for cell labeling and imaging | CELLFE, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12391976-B2 | Methods, kits, and compositions for processing extracellular molecules | 10X GENOMICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240150812-A1 | METHODS, KITS, AND COMPOSITIONS FOR PROCESSING EXTRACELLULAR MOLECULES | 10X GENOMICS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11851700-B1 | Methods, kits, and compositions for processing extracellular molecules | 10X GENOMICS, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230382966-A1 | NOVEL KLOTHO INTERACTION SITE IN THE C-TERMINUS OF FGF23 | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2023-11-30 | — | — | US | disclosed |
| US-20230235357-A1 | MICROFLUIDIC LASER-ACTIVATED INTRACELLULAR DELIVERY SYSTEMS AND METHODS | CELLINO BIOTECH INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20220298461-A1 | METHODS AND SYSTEMS FOR CELL LABELING AND IMAGING | CELLFE, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220213422-A1 | METHODS AND SYSTEMS FOR INTRACELLULAR DELIVERY AND PRODUCTS THEREOF | CELLFE, INC. (US) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382966-A1 | NOVEL KLOTHO INTERACTION SITE IN THE C-TERMINUS OF FGF23 | FGF23, PTH1R, PTMS | F11 1247/4885MSTN 65/4885GLP1R 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.